Eli Lilly (LLY)
734.57
-16.88 (-2.25%)
NYSE · Last Trade: May 10th, 4:03 PM EDT
Detailed Quote
Previous Close | 751.45 |
---|---|
Open | 752.01 |
Bid | 736.15 |
Ask | 737.00 |
Day's Range | 733.00 - 762.01 |
52 Week Range | 677.09 - 972.53 |
Volume | 4,072,637 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.82%) |
1 Month Average Volume | 4,626,744 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Global markets digested a week packed with trade breakthroughs, monetary policy signals, and digital asset milestones.
Via Benzinga · May 9, 2025
U.S. stocks rally amid steady Fed rates, strong Disney and AMD earnings, but Alphabet falls on Apple concerns.
Via Chartmill · May 9, 2025
Via The Motley Fool · May 8, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · May 8, 2025
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · May 8, 2025
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via Benzinga · May 8, 2025
Via The Motley Fool · May 8, 2025
This isn't just any growth stock.
Via The Motley Fool · May 8, 2025
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
Via Benzinga · May 8, 2025
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
Via Benzinga · May 7, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Via Chartmill · May 7, 2025
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition.
Via Benzinga · May 7, 2025
Animal health company Elanco (NYSE:ELAN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.
Via StockStory · May 7, 2025
Via The Motley Fool · May 7, 2025
The company said the reorganization plan would eliminate $1.15 billion in debt from its balance sheet
Via Stocktwits · May 7, 2025
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now staring at a bankruptcy process to reorganize its finances.
Via Benzinga · May 6, 2025
Good news for Hims & Hers stock spooks Lilly and Novo investors.
Via The Motley Fool · May 6, 2025
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at boosting domestic drug manufacturing.
Via Benzinga · May 6, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via Chartmill · May 6, 2025
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?
Via MarketBeat · May 6, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · May 6, 2025